中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 多模态人工智能系统全国重点实验室
  5. 互联网大数据与安全信息学研究中心
Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis

文献类型：期刊论文

作者Wang, Hong2,6; Xie, Xiaoya5; Zu, Quannan4; Lu, Ming4; Chen, Rongfa3; Yang, Zhiren3; Gao, Yongqiang2; Tang, Zhangui1
刊名DIABETES THERAPY
出版日期2022-12-09
页码15
ISSN号1869-6953
关键词Percutaneous coronary intervention Type 2 diabetes mellitus Ticagrelor Dual antiplatelet therapy Monotherapy Bleeding
DOI10.1007/s13300-022-01350-9
通讯作者Wang, Hong(iriswh2014@163.com)
英文摘要Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of coronary artery disease (CAD). In patients with acute coronary syndrome (ACS), guidelines recommend a potent P2Y12 inhibitor in addition to aspirin. For those with complicated and advanced CAD requiring complex percutaneous coronary intervention (PCI), the risk for adverse ischemic events is even higher. Prolonged dual antiplatelet therapy (DAPT) use is controversial. A new antiplatelet regimen after PCI should be considered. In this analysis, we aimed to systematically show the impact of long-term ticagrelor monotherapy after a short course of DAPT use on the outcomes in patients with T2DM following PCI.Methods: Electronic databases were searched for relevant publications. Studies that were based on patients with T2DM and that included patients with T2DM were selected on the basis of the inclusion and exclusion criteria. Statistical analysis was carried out with RevMan software. The data are presented as risk ratios (RR) with 95% confidence intervals (CI).Results: A total of 8621 patients were included in this analysis, whereby 4357 participants with T2DM were assigned to ticagrelor monotherapy and 4264 were assigned to DAPT. Our results showed long-term ticagrelor monotherapy after a short course of DAPT use to be associated with a significantly lower risk of major adverse cardiac events (RR 0.86, 95% CI 0.77-0.98; P = 0.02) and all-cause mortality (RR 0.77, 95% CI 0.60-0.98; P = 0.03). However, no significant difference was observed in cardiac death, myocardial infarction, stroke, stent thrombosis, or repeated revascularization. Ticagrelor monotherapy was associated with significantly lower risk of thrombolysis in myocardial infarction (TIMI) defined minor or major bleeding (RR 0.71, 95% CI 0.54-0.93; P = 0.01) compared with the DAPT regimen.Conclusion: Long-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.
WOS关键词DUAL-ANTIPLATELET THERAPY ; SAFETY ; EFFICACY ; ASPIRIN ; TRIALS ; IMPACT
资助项目Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project ; Guangxi Nanning Qingxiu District Science and Technology Development Project ; [S2017077] ; [2014S06]
WOS研究方向Endocrinology & Metabolism
语种英语
出版者SPRINGER HEIDELBERG
WOS记录号WOS:000895663700001
资助机构Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project ; Guangxi Nanning Qingxiu District Science and Technology Development Project
源URL[http://ir.ia.ac.cn/handle/173211/50824]  
专题自动化研究所_复杂系统管理与控制国家重点实验室_互联网大数据与安全信息学研究中心
通讯作者Wang, Hong
作者单位1.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China
2.Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Cardiol, Nanning 530021, Guangxi, Peoples R China
3.Chinese Acad Sci, Inst Automation, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China
4.Tianjin Univ, Coll Management & Econ, Tianjin 300072, Peoples R China
5.Macau Univ Sci & Technol, Macau, Peoples R China
6.Jinan Univ, Guangzhou 510632, Guangdong, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Hong,Xie, Xiaoya,Zu, Quannan,et al. Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis[J]. DIABETES THERAPY,2022:15.
APA Wang, Hong.,Xie, Xiaoya.,Zu, Quannan.,Lu, Ming.,Chen, Rongfa.,...&Tang, Zhangui.(2022).Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis.DIABETES THERAPY,15.
MLA Wang, Hong,et al."Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis".DIABETES THERAPY (2022):15.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。